content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Juno Therapeutics, Inc. (JUNO)

41.91
0.06
(0.14%)
Sep 11, 4:00PM EDT
content_middle

Juno Therapeutics (JUNO) is a clinical-stage company developing cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. JUNO’s goal is to re-engage the body’s immune system to treat cancer.  Its technologies genetically engineer a patient’s own T cells to recognize and kill cancer cells. These cellular therapies have the potential to be effective regardless of the type of previous treatments patients have experienced and may avoid the long-term side effects associated with current treatments. JUNO uses two different technologies to target cancer cells and activate T cells, CARs and TCRs.

Previous Close: 
41.85
Open: 
42.25
Bid: 
41.45
Ask: 
41.92
1yr Target Price: 
35.75
Day's Range: 
40.26 - 42.35
52wk Range: 
17.52 - 44.60
Volume: 
2193266
Average Daily Volume: 
2489560
Market Capitalization: 
4.40B
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
104896000M
content_right

Pages